These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Impact of vaccination on meningococcal epidemiology. Stefanelli P; Rezza G Hum Vaccin Immunother; 2016 Apr; 12(4):1051-5. PubMed ID: 26512927 [TBL] [Abstract][Full Text] [Related]
4. An unwanted guest: Neisseria meningitidis - carriage, risk for invasive disease and the impact of vaccination with insight on Italy incidence. Gianchecchi E; Piccini G; Torelli A; Rappuoli R; Montomoli E Expert Rev Anti Infect Ther; 2017 Jul; 15(7):689-701. PubMed ID: 28524748 [TBL] [Abstract][Full Text] [Related]
5. Reduction in Neisseria meningitidis infection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994-2012 series. de Waure C; Miglietta A; Nedovic D; Mereu G; Ricciardi W Hum Vaccin Immunother; 2016; 12(2):467-73. PubMed ID: 26308192 [TBL] [Abstract][Full Text] [Related]
6. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation. Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880 [TBL] [Abstract][Full Text] [Related]
7. [Meningococcal vaccines: from polysaccharide to conjugate vaccines]. Cohen R; Levy C Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368 [TBL] [Abstract][Full Text] [Related]
8. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy. Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162 [TBL] [Abstract][Full Text] [Related]
9. Invasive bacterial diseases: national surveillance in Italy and vaccination coverage in the Local Health Agency 4 "Chiavarese", Liguria region (Italy). Trucchi C; Zoppi G J Prev Med Hyg; 2012 Jun; 53(2):120-4. PubMed ID: 23240174 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model. Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896 [TBL] [Abstract][Full Text] [Related]
11. Prevention of Meningococcal Infection in the United States: Current Recommendations and Future Considerations. Baker CJ J Adolesc Health; 2016 Aug; 59(2 Suppl):S29-37. PubMed ID: 27449147 [TBL] [Abstract][Full Text] [Related]
12. Genomic epidemiology of age-associated meningococcal lineages in national surveillance: an observational cohort study. Hill DM; Lucidarme J; Gray SJ; Newbold LS; Ure R; Brehony C; Harrison OB; Bray JE; Jolley KA; Bratcher HB; Parkhill J; Tang CM; Borrow R; Maiden MC Lancet Infect Dis; 2015 Dec; 15(12):1420-8. PubMed ID: 26515523 [TBL] [Abstract][Full Text] [Related]
13. Impact of meningococcal vaccination on carriage and disease transmission: A review of the literature. Balmer P; Burman C; Serra L; York LJ Hum Vaccin Immunother; 2018 May; 14(5):1118-1130. PubMed ID: 29565712 [TBL] [Abstract][Full Text] [Related]
14. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia. Marshall HS; Lally N; Flood L; Phillips P Med J Aust; 2020 Feb; 212(2):89-93. PubMed ID: 31909501 [TBL] [Abstract][Full Text] [Related]
15. Outer membrane vesicles extracted from Neisseria meningitidis serogroup X for prevention of meningococcal disease in Africa. Acevedo R; Zayas C; Norheim G; Fernández S; Cedré B; Aranguren Y; Cuello M; Rodriguez Y; González H; Mandiarote A; Pérez M; Hernández M; Hernández-Cedeño M; González D; Brorson SH; Rosenqvist E; Naess L; Tunheim G; Cardoso D; García L Pharmacol Res; 2017 Jul; 121():194-201. PubMed ID: 28495657 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Meningococcal Vaccines at Reducing Invasive Meningococcal Disease and Pharyngeal Neisseria meningitidis Carriage: A Systematic Review and Meta-analysis. McMillan M; Chandrakumar A; Wang HLR; Clarke M; Sullivan TR; Andrews RM; Ramsay M; Marshall HS Clin Infect Dis; 2021 Aug; 73(3):e609-e619. PubMed ID: 33212510 [TBL] [Abstract][Full Text] [Related]
17. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers. McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636 [TBL] [Abstract][Full Text] [Related]
18. Introduction of a second MenB vaccine into Europe - needs and opportunities for public health. Findlow J; Nuttens C; Kriz P Expert Rev Vaccines; 2019 Mar; 18(3):225-239. PubMed ID: 30821535 [TBL] [Abstract][Full Text] [Related]
19. Considerations for controlling invasive meningococcal disease in high income countries. Holst J; Nøkleby H; Bettinger JA Vaccine; 2012 May; 30 Suppl 2():B57-62. PubMed ID: 22607900 [TBL] [Abstract][Full Text] [Related]
20. Past, present, and future policy considerations regarding meningococcal vaccination in the United States. Clements DE; Olaiya T; Burman C; Herrera-Restrepo O; Sohn WY; Folaranmi T; Abbing-Karahagopian V; Marshall GS; Conway JH Expert Rev Vaccines; 2024; 23(1):845-861. PubMed ID: 39230002 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]